Exelixis and Boehringer Ingelheim in $354 million autoimmune disease deal
This article was originally published in Scrip
Executive Summary
Exelixis will receive up to $354 million from Boehringer Ingelheim to develop sphingosine-1 phosphate type 1 receptor (S1P1) agonists for autoimmune diseases.